{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:46:27Z","timestamp":1775677587341,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.rmed.2017.09.002","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T03:16:02Z","timestamp":1504581362000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Effect of budesonide\/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study"],"prefix":"10.1016","volume":"132","author":[{"given":"Gary T.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor","family":"Sk\u00e4rby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin","family":"Jorup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Sandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Trudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmed.2017.09.002_bib1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1378\/chest.06-1610","article-title":"Impact of COPD exacerbations on patient-centered outcomes","volume":"131","author":"Cote","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2017.09.002_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/COPD.S34186","article-title":"Exacerbation frequency and course of COPD","volume":"7","author":"Halpin","year":"2012","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"10.1016\/j.rmed.2017.09.002_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1465-9921-14-116","article-title":"Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial","volume":"14","author":"Beeh","year":"2013","journal-title":"Respir. Res."},{"issue":"11","key":"10.1016\/j.rmed.2017.09.002_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Catalu\u00f1a","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2017.09.002_bib5","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD Report 2017. http:\/\/goldcopd.org\/gold-2017-global-strategy-diagnosis-management-prevention-copd\/. Accessed 16 November, 2016."},{"issue":"12","key":"10.1016\/j.rmed.2017.09.002_bib6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2017.09.002_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1586\/14787210.4.1.101","article-title":"Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease","volume":"4","author":"Martinez","year":"2006","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"5","key":"10.1016\/j.rmed.2017.09.002_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"issue":"8","key":"10.1016\/j.rmed.2017.09.002_bib9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.rmed.2017.09.002_bib10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2017.09.002_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1465-9921-10-59","article-title":"Efficacy of salmeterol\/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study","volume":"10","author":"Jenkins","year":"2009","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.rmed.2017.09.002_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.rmed.2017.09.002_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rmed.2011.07.020","article-title":"Effect of budesonide\/formoterol pMDI on COPD exacerbations: a double-blind, randomized study","volume":"106","author":"Sharafkhaneh","year":"2012","journal-title":"Respir. Med."},{"issue":"14","key":"10.1016\/j.rmed.2017.09.002_bib14","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","article-title":"Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial","volume":"68","author":"Tashkin","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.rmed.2017.09.002_bib15","article-title":"Guidance for Industry; Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research","year":"2016","journal-title":"."},{"issue":"2","key":"10.1016\/j.rmed.2017.09.002_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","article-title":"Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease","volume":"106","author":"Anthonisen","year":"1987","journal-title":"Ann. Intern Med."},{"issue":"6","key":"10.1016\/j.rmed.2017.09.002_bib17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/fampra\/cmt055","article-title":"Predictors of exacerbations of asthma and COPD during one year in primary care","volume":"30","author":"Al-ani","year":"2013","journal-title":"Fam. Pract."},{"issue":"10","key":"10.1016\/j.rmed.2017.09.002_bib18","doi-asserted-by":"crossref","first-page":"e109721","DOI":"10.1371\/journal.pone.0109721","article-title":"Predictors of exacerbations in chronic obstructive pulmonary disease\u2013results from the Bergen COPD cohort study","volume":"9","author":"Huseb\u00f8","year":"2014","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.rmed.2017.09.002_bib19","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.290.17.2301","article-title":"Contemporary management of chronic obstructive pulmonary disease: scientific review","volume":"290","author":"Sin","year":"2003","journal-title":"JAMA"},{"issue":"9691","key":"10.1016\/j.rmed.2017.09.002_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0140-6736(09)61250-2","article-title":"Budesonide and the risk of pneumonia: a meta-analysis of individual patient data","volume":"374","author":"Sin","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2017.09.002_bib21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2147\/COPD.S128358","article-title":"Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies","volume":"12","author":"Hollis","year":"2017","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117303141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611117303141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:36:41Z","timestamp":1760614601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611117303141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":21,"alternative-id":["S0954611117303141"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2017.09.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of budesonide\/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2017.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}